Gynaecology illustrated. and the results this may have for the future potential of the child. Gestational edema is included as a separate topic from weight gain in. Gynaecology Illustrated - Free ebook download as PDF File .pdf) or read book online for free. Gynaecology Illustrated 6th Edition. This is a visual presentation of Gynaecology aimed at undergraduate medical students. The highly effective format is ideal.
|Language:||English, Spanish, Japanese|
|Genre:||Health & Fitness|
|Distribution:||Free* [*Sign up for free]|
One of the Best selling books related to the field of Gynaecology is the Gynaecology illustrated series. This 6th edition is the latest and provides. The first edition of Gynaecology Illustrated appeared in This soft-cover budget-edition is aimed at medical students and primary health care staff. Gynaecology. AN ILLUSTRATED COLOURTBtt. Joan Pitkin BSCFRCSFRCOG. Consultant Obstetrician and Gynaecologist. Northwick Park & St Mark's Hospital.
Obstetrics and gynecology, Volume 1. Clinical Strategies Gynecology and Obstetrics. Blueprints Series: Obstetrics and Gynecology.
Oxford American Handbook of Obstetrics and Gynecology. Case Files: Manual of Outpatient Gynecology. Deja review: Blueprints Obstetrics and Gynecology, 5th Edition.
Doppler Ultrasound in Obstetrics and Gynecology. Hematological Complications in Obstetrics, Pregnancy, and Gynecology. Finding combinations of predictive, robust, biomarkers is computationally intensive, and with many hundreds of proteins, exhaustive searches of combinations of up to 20 proteins is not feasible. To this end, we developed a strategy for identification of highly predictive unique signatures using hierarchical exclusion of individual proteins.
By design, this led to the discovery of many signatures that did not contain MUCIN, although this protein was the strongest univariate biomarker among the ones we studied. Our top-ranking model achieved a sensitivity of 0.
The difference in performance between our study and that by Boylan and colleagues 18 could be due to geographic origin of the cohorts USA and Sweden , biological nature of the sample i. Boylan and colleagues 18 used 21 women with benign conditions and 21 with late-stage ovarian cancer, as compared to 71 and 56 in our study. Another study by Han and colleagues 16 reported a sensitivity of 0.
Our top-ranked model had a sensitivity of 0. Similar to the results of these previous studies 16 , 18 , the performance of our models in the test-proportion of the discovery data is very good, with some models showing perfect classification. We also evaluated the selected models in two replication cohorts and found the performance similar, while somewhat lower than in the discovery set. This either implies that there are underlying differences between the cohorts, such as in pre-analytical conditions, or that the models are over-trained with respect to the samples in the discovery cohort.
The performance in the test-proportion of the discovery cohort should, therefore, be considered less certain than the results obtained in the replication cohorts.
In our study, the benign tumors and the cancer samples from the 2nd replication cohort differ in pre-analytical context, which could explain part of the lower performance as compared to using the 1st replication cohort. We then implemented our final, proof-of-concept, model into a custom assay reporting in absolute protein concentrations. Since the readout for the custom assay differ from the standard PEA-readout used in the discovery and first two replication cohorts the model coefficients needed to be retrained.
This could lead to overfitting of the model to the investigated cohort. As the performance in these two subsets did not essentially differ, the retraining of the models does not seem to be overfitted with respect to the samples used. We, therefore, used a 5-fold cross-validation schema using the entire third replication cohort for the final model fitting. This does however not necessarily guarantee that the performance of the model will remain the same in additional cohorts with e.
We also noted that the performance of our model is slightly better in the third replication cohort, where the AUC was 0. This could be due to the wider dynamic range of the custom assay, but indicates that the performance of the model is robust.
A second contributing factor could be that cases are compared to a group diagnosed with benign tumors, representing heterogenous conditions.
This highlights the importance of understanding the context in which a biomarker test is to be used as compared to the setting used for development of the model. From this observation, it is clear that there are samples that will still be hard to find or distinguish using the biomarker model presented here. TACSTD2 tumor-associated calcium signal transducer 2 expression has been associated with decreased survival of ovarian cancer and proposed as a prognostic factor 24 , and a biomarker for targeted therapy Lecture Notes : Psychiatry 11th Ed.
Lecture Notes : Urology 7th Ed. Medical Microbiology and Infection at a Glance 4th Ed. Medical Pharmacology at a Glance 8th Ed. Medical Sciences by Naish et al 2nd Ed. Metabolism at a Glance 4th Ed. MRI at a Glance 2nd Ed. Neurology and Neurosurgery Illustrated 5th Ed. Oxford Handbook of Clinical Medicine 10th Ed.